Tardive dyskinesia
RecruitingEfficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia
- Disease:Tardive dyskinesia
- Substances:–
Bulgaria- Participants:18–64 years · 65+ years
- Sponsor:Neurocrine Biosciences Inc.
Rare diseases
Investigational molecules
Locations
Back to Bulgaria14 clinical trials in Cherven Bryag, Bulgaria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
Bulgaria
BulgariaThe busiest research cities in the country
What the registry says about research in the country
Extensive clinical research focusing on major depressive disorder (MDD) evaluates novel therapeutic approaches and treatment combinations for patients with inadequate response to standard medications.
Multiple trials are exploring innovative compounds to enhance the effectiveness of existing antidepressant therapies.
Ongoing investigations into schizophrenia treatment focus on developing adjunctive therapies for patients with inadequately controlled symptoms.
Research emphasizes the evaluation of novel therapeutic combinations to improve patient outcomes.
Clinical trials examining new treatments for Alzheimer's Disease psychosis, with particular attention to managing psychiatric symptoms in affected patients.
Studies focus on both short-term efficacy and long-term safety of novel therapeutic approaches.
Tell us about your condition – we search every trial in Europe and connect you with the right site.